Role of RhoA in small AAA growth
Role of RhoA in small AAA growth
批准号:
9562859
负责人:
Zhenheng Guo
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-10-01 至 2022-09-30
关键词:
AbdomenAbdominal Aortic AneurysmAddressAdhesionsAgeAneurysmAnimal ModelAortaBiological AssayBiological MarkersBloodBlood VesselsCaliberCaringCell CountClinicalClinical TrialsClinical assessmentsDataData SetDiagnosisDiseaseEarly DiagnosisElastinEndothelial CellsEndotheliumEnzyme-Linked Immunosorbent AssayEvaluationFailureFeasibility StudiesFutureGoalsGrowthHumanIn VitroInfiltrationInjuryLeadLeukocytesLifeLipopolysaccharidesMatrix MetalloproteinasesMeasurementMeasuresMediatingMedicalMethodsMusNatural HistoryOperative Surgical ProceduresPathologyPatientsPermeabilityPharmacologyPlayPreventionProcessProteinsResearch PriorityRiskRisk AssessmentRisk FactorsRoleRuptureRuptured Abdominal Aortic AneurysmSerumSmooth Muscle MyocytesStainsSudden DeathSurgeonTestingTimeTissuesTransferaseVascular DiseasesVeteransWomanbaseclinical riskexoenzymefasudilfollow-uphuman subjecthuman tissueimaging studyinhibitor/antagonistinnovationmenmonocytemouse modelnovelnovel therapeuticspopulation basedpredictive markerpreventpreventable deathprospectiverepairedrhoA GTP-Binding Proteinscreeningtranslational studytreatment strategy
中文摘要
项目摘要/摘要
腹主动脉瘤(Aaa)是一种血管疾病,体内的主要血管可以
退化,气球大小导致最终破裂和猝死。目前,AAA通过以下方式识别
作为筛查研究的一部分或在评估其他腹部疾病时附带进行的影像检查
病理学。鉴于预测破裂最重要的临床参数是最大的主动脉直径,
2.0厘米或以下的正常主动脉不需要进一步评估,而男性的大动脉5.5厘米和5.0厘米。
女性的CM需要手术治疗。基于大量退伍军人群体的前瞻性分析,20%的退伍军人
小动脉(3.0-5.4厘米)会迅速生长,并可能对退伍军人的生命构成威胁。不幸的是,
我们不知道哪些小型AAA会快速增长,有些增长缓慢,还有一些根本就没有增长。未能识别
快速增长的小型AAA将导致一定但可以预防的死亡。因此,迫切需要发展
快速生长的小AAA的预测性标志物,以便及时进行手术。
小AAA的医疗管理是退伍军人护理中的首要研究重点之一
血管疾病。我们希望建立我们的中心假设,即RhoA介导单核细胞与
主动脉内皮细胞导致内皮细胞屏障损伤,继而单核细胞迁移,主动脉壁增厚
破坏,以及最终的小AAA增长。这一假设将通过以下具体目标进行检验:1)
确定AAA增长期受试者单核细胞中RhoA的活化是否
会导致单核细胞黏附增加和内皮屏障损伤,2)确定
在动物模型中单核细胞RhoA在AAA的形成中起因果作用,3)确定高水平
从小AAA患者的单核细胞中分离的RhoA蛋白活性将预测
小型AAA的生长(>;0.1厘米/年)。目前的研究表明,RhoA作为生物标记物的可能性
对于AAA形成和生长过程中的疾病。RhoA和单核细胞活性被鉴定为高表达
在AAA患者的血清和主动脉组织中,与年龄匹配的对照组相比,RhoA的作用
将受试者与生长中的AAA或稳定的AAA进行比较,目前尚不清楚。到目前为止,还缺乏
从人体组织中获得的数据的可译性(在疾病过程的后期)或从
给患有小腹主动脉瘤的人类患者建立动物模型。本项目的创新之处在于将两者联系起来
将RhoA和单核细胞活性用于生物标志物的主导机制,导致未来的新技术
控制小AAA生长的治疗方法。这是一项使用人类经验丰富的受试者进行的翻译研究
可用1,169名具有小型AAA(3.0-5.4厘米)的退伍军人在10年内收集,以使
完成拟议的研究是可行的。最终,我们希望收集的数据将开启一种可能性
确定预测和限制小型AAA增长的方法。
英文摘要
Project Summary/Abstract
An abdominal aortic aneurysm (AAA) is a vascular condition where a major blood vessel in the body can
degenerate, balloon in size leading to ultimate rupture and sudden death. Currently, an AAA is identified through
imaging studies performed as part of a screening study or incidentally when evaluating for other abdominal
pathology. Given that the most important clinical parameter in predicting rupture is the maximal aortic diameter,
a normal aorta of 2.0 cm or less requires no further evaluation, whereas a large aorta >5.5 cm in men and >5.0
cm in women requires surgery. Based upon a large VA population based prospective analysis, 20% of veterans
with small aortas (3.0-5.4 cm) will grow rapidly and may pose a threat to the life of the veteran. Unfortunately,
we do not know which small AAAs will grow rapidly, others slowly, and still others not at all. Failure to identify
rapidly growing small AAAs will lead to a certain but preventable death. Thus, there is a critical need to develop
predictive markers for rapidly growing small AAAs so that surgery can be performed timely.
The medical management of small AAA is one of the top research priorities in the care of the Veterans with
vascular disease. We hope to establish our central hypothesis that RhoA mediated monocyte adhesion to the
aortic endothelium leads to endothelial barrier injury, subsequent monocyte transmigration, increased aortic wall
destruction, and ultimate small AAA growth. This hypothesis will be tested by the following specific aims: 1) To
determine whether the activation of RhoA in monocytes from Veteran subjects with a growing small AAA
will lead to increased monocyte adhesion, and endothelial barrier injury, 2) To determine whether
monocyte RhoA plays a causal role in AAA formation in the animal model, 3) To determine whether high
RhoA protein activity isolated in the monocytes from Veteran subjects with small AAA will predict the
growth of the small AAA (>0.1 cm/year). Current studies have shown the possibility of RhoA as a biomarker
for disease in both AAA formation and growth. RhoA and monocyte activity were identified to be highly expressed
in both the serum and aortic tissue from subjects with AAA compared to age-matched controls, The role of RhoA
in comparing human subjects with growing AAA or stable AAA has yet to be elucidated. To date, there is a lack
of translatability of the data obtained from tissue in human subjects (late in the disease process) or findings from
animal models to the human patient with small AAAs. The innovation of this project is the connection between
the use of RhoA and monocyte activity into an overarching mechanism of biomarkers, leading to future novel
therapies to control small AAA growth. This is a translational study using human Veteran subjects with the readily
available 1,169 veterans identified with small AAAs (3.0-5.4 cm) collected over a 10-year period to make the
completion of the proposed study feasible. Ultimately, we hope that the data collected will open the possibility of
identifying approaches to both predicting and limiting small AAA growth.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of RhoA in small AAA growth
-
批准号:10295147
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Zhenheng Guo
-
依托单位:
Role of RhoA in small AAA growth
-
批准号:10683701
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Zhenheng Guo
-
依托单位:
Role of RhoA in small AAA growth
-
批准号:10038806
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Zhenheng Guo
-
依托单位:
iPLA2 as a Target in Vascular Inflammation, Neointima Formation, and Restenosis
-
批准号:8967092
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Zhenheng Guo
-
依托单位:
iPLA2 as a Target in Vascular Inflammation, Neointima Formation, and Restenosis
-
批准号:9275392
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Zhenheng Guo
-
依托单位:
ROLE OF CALCIUM-INDEPENDENT PHOSPHOLIPASE A2BETA IN HIGH GLUCOSE-INDUCED
-
批准号:8361445
-
项目类别:
-
资助金额:$0.83万
-
财政年份:2011
-
负责人:Zhenheng Guo
-
依托单位:
A Novel Mechanism by which iPLA2 Links Diabetes to Cardiovascular Diseases
-
批准号:7834334
-
项目类别:
-
资助金额:$25.81万
-
财政年份:2009
-
负责人:Zhenheng Guo
-
依托单位:
A Novel Mechanism by which iPLA2 Links Diabetes to Cardiovascular Diseases
-
批准号:7766988
-
项目类别:
-
资助金额:$36.63万
-
财政年份:2008
-
负责人:Zhenheng Guo
-
依托单位:
A Novel Mechanism by which iPLA2 Links Diabetes to Cardiovascular Diseases
-
批准号:7579014
-
项目类别:
-
资助金额:$36.63万
-
财政年份:2008
-
负责人:Zhenheng Guo
-
依托单位:
A Novel Mechanism by which iPLA2 Links Diabetes to Cardiovascular Diseases
-
批准号:8236894
-
项目类别:
-
资助金额:$36.26万
-
财政年份:2008
-
负责人:Zhenheng Guo
-
依托单位:
A Novel Mechanism by which iPLA2 Links Diabetes to Cardiovascular Diseases
-
批准号:7373470
-
项目类别:
-
资助金额:$36.63万
-
财政年份:2008
-
负责人:Zhenheng Guo
-
依托单位:
海外基金